Latest LEO Pharma News & Updates

See the latest news and media coverage for LEO Pharma. We track all announcements, press releases, and industry mentions in real time, all in one place.

LEO Pharma

Global pharmaceutical company focused on dermatology and critical care

leo-pharma.com

Headquarters: Ballerup, Denmark
Founded year: 1908
Company type: Private company
Number of employees: 5,000–5,600
Industry: Pharmaceuticals

Last updated October 29

Latest news about LEO Pharma

In short: LEO Pharma advanced toward a Copenhagen IPO, completed two acquisitions, and posted strong 2026 growth.

Company announcements

October 29 LEO Pharma

LEO Pharma releases its 2020 Annual Report

The report details financial results, R&D pipeline advancements, the 2030 strategy, and ESG performance amid the pandemic.

September 18 LEO Pharma

LEO Pharma acquires dersimelagon and receives FDA priority review

The FDA accepted the NDA with a PDUFA date in Feb 2027. The acquisition from Tanabe Pharma strengthens LEO's pipeline for rare skin diseases.

August 18 LEO Pharma

LEO Pharma delivers strong first-half 2026 financial results

The company highlights portfolio expansion through targeted acquisitions and advanced clinical trials for rare dermatological conditions.

August 14 LEO Pharma

LEO Pharma elects Henriette Mersebach to board

She brings deep pharmaceutical R&D and innovation expertise, having held senior roles at ALK and Novo Nordisk.

Media coverage

October 16 Avisen Danmark

Leo Pharma takes over American pharmaceutical company

Leo Pharma is located in Ballerup, where the company has both its headquarters and production facilities. Photo: Liselotte Sabroe/Ritzau Scanpix The Danish pharmaceutical company Leo Pharma has been on...

October 14 Børsen

Is Leo Pharma ready for the stock market? Could become the largest listing since Ørsted

Denmark's oldest pharmaceutical company may soon become available to everyone, as Leo Pharma is expected to announce its readiness for a stock market listing in Copenhagen within the coming weeks...

October 8 CheckRare

Priority Review for Dersimelagon in the Treatment of Erythropoietic Protoporphyria and X-Linked Protoporphyria | CheckRare

Lukasz Jarzyna, LEO Pharma, discusses the Priority Review for dersimelagon in the treatment of EPP and XLP.

September 29 Børsen

Media: Leo Pharma sets possible date for stock market debut

The long-awaited listing of Leo Pharma will probably take place around November 25 or thereabouts, sources tell Berlingske. It is also the last call...

Never miss news about LEO Pharma

Track LEO Pharma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

LEO Pharma competitors & trending companies

Browse news for competitors to LEO Pharma and other trending companies.